

## **Burrill & Company's Merchant Banking Group Launches Institutional Equities Research Division with Addition of Jason Zhang, Ph.D., as Senior Research Analyst**

SAN FRANCISCO, January 5, 2011—Burrill & Company is pleased to announce that Jason Zhang, Ph.D., has joined Burrill Merchant Banking as a senior research analyst to cover the biotechnology industry. Dr. Zhang will provide proprietary research, insight and analysis of both a select list of companies as well as broader industry trends.

“The addition of Jason is another step in our ongoing effort to better meet the needs of the life sciences companies and institutional investors we serve,” says G. Steven Burrill, CEO of Burrill & Company, a global life sciences financial services firm. “We expect to continue to build out our research and banking capabilities globally in the year ahead.”

Dr. Zhang has more than 16 years of experience on Wall Street and in the biopharmaceutical industry. Most recently he served as a managing director and senior analyst at BMO Capital Markets. Dr. Zhang ranked third in the 2009 Financial Times Star Mine Awards for the biotechnology industry and ranked fifth in the 2009 Wall Street Journal Best On The Street Stock Analysts for biotechnology.

Jason holds an MBA from The Kelly School of Business at Indiana University; a Ph.D. in Cell, Molecular, and Neurosciences/Botanic Sciences from University of Hawaii, an M.S. from China Agricultural University, Beijing, China in Plant Pathology; and a B.S. in Plant Protection from Central China (Hubei) Agricultural University. Prior to working on Wall Street, Dr. Zhang worked as a Postdoctoral Scientist at Eli Lilly.

“Jason is a well-respected analyst with deep industry experience,” says Stephen Hurly, CEO of Burrill Merchant Banking. “Combining Jason’s long tenure, strong buy-side contacts and deep technical understanding provides us another resource to provide solid fundamental insight to both our institutional and corporate clients. In addition, Jason’s strong international contacts will further complement our focus and ability to support our clients’ global goals.”

### **About Burrill Merchant Banking**

Burrill Merchant Banking provides life sciences companies with access to financial resources through global capital and a blend of complementary financial advisory services on public or private financings and cross-border transactions, including M&A, strategic partnerships, spin-outs, and strategic development. It provides companies enhanced access to public market investors through its Institutional Equities business. Our team has extensive experience and a comprehensive network to help life sciences companies access capital and strategically build their businesses.

### **About Burrill & Company**

Founded in 1994, Burrill & Company is a diversified global financial services firm focused on the life sciences industry. With \$1.5 billion in assets under management, the firm's businesses include

venture capital/private equity, merchant banking, and media. By leveraging the scientific and business networks of its team, Burrill & Company has established unrivaled access and visibility in the life sciences industry. This unique combination of resources and capabilities enables the company to provide life sciences companies with capital, transactional support, management expertise, insight, market intelligence, and analysis through its investments, conferences, and publications. Headquartered in San Francisco, the company oversees a global network of offices throughout the United States, Latin America, Europe, and Asia. For more information visit: [www.burrillandco.com](http://www.burrillandco.com).

**Contact:**

Daniel Levine  
Managing Director  
Burrill & Company  
[dlevine@b-c.com](mailto:dlevine@b-c.com)  
415-591-5449